Amyloid biomarkers are a prerequisite: only patients with confirmed brain Aβ accumulation (positive amyloid PET or CSF Aβ42/tau ratio consistent with AD) should be treated [148,149,150]. The gene discussed is MAPT; the disease is Alzheimer disease.